Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat

Next Previous
Trial Profile

A reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 10 Aug 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Migalastat (Primary)
  • Indications Fabry's disease
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 07 Aug 2017 According to an Amicus Therapeutics media release, 179 patients (treatment naive and ERT switch) reimbursed Galafold as of July 31, 2017.
  • 09 May 2017 According to an Amicus Therapeutics media release, 100 patients (treatment naive and ERT switch) reimbursed Galafold as of April 30, 2017
  • 09 Jan 2017 According to an Amicus Therapeutics media release, 61 patients are being treated on reimbursed Galafold as of December 31, 2016. The company targets to treat 300 patients by year-end 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top